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Loss of cyclin-dependent kinase inhibitor genes and chromosome 9
karyotypic abnormalities in human bladder cancer cell lines
J Southgate', J Proffitt'*, P Roberts2, B Smith' and P Selby'
'ICRF Cancer Medicine Research Unit and2Cytogenetics Unit, St. James's University Hospital, Leeds LS9 7TF, UK.
Sary Loss of cell cycle control through the structural or functional aberration of checkpoint genes and
their products is a potentially Important process in carcinogenesis. In this study, a panel of well-characterised
established human bladder cancer cell lines was screened by the polymerase chain reaction for homozygous
loss of the cyclin-dependent kinase inhibitor genes pI5, pl6 and p27. The results demonstrate that, whereas
there was no genetic loss of p27, homozygous deletion of both pi5 and pl6 genes occurred in seven of 13
(54%) independent bladder cel lines tested Differential loss of either the pl5 or pl6 gene was not seen. The
pl5 and pl6 genes are lnown to be juxtaposed on chromosome 9p21 at the locus of a putative tumour-
suppressor gene involved in the initiation of bladder cancer. Cytogenetic analysis of the cell lnes revealed
karyotypes ranging from near diploid to near pentaploid with complex rearrangements of some chromosomes
and a high prevaknce of chromosome 9p rearrangements, although all cell lines contained at least one
cytogenetically normal 9p21 region. These observations support a role forpl5/pl6 gene inactivation in bladder
carcuiogenesis and/or the promotion of cell growth in vitro and lend support to the hypothesis that
homozygous deletion centred on 9p21 is a mechanism by which both p15 and p16 genes are co-inactivated.
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Transitional cell carcinoma (TCC) is the most common
cancer of the urinary bladder and orginates from the normal
stratified transitional epithelium, the urothelium. The natural
history of TCC is unclear as it is currently not possible to
distiguish the 3% subgroup ofpatients with superficial non-
invasive papillary disease who will progress to muscle-
invasive malignant disease from those patients in whom the
diseas is less aggressive. It is thought that the homozygous
loss of a tumour-suppressor gene may be the initiating factor
in bladder cancer and interest has centred on chromosome 9,
which shows a high rate of allelic loss that is both stage and
grade independent (Cairns et al., 1993; Miyao et al., 1993;
Ruppert et al., 1993; Stadler et al., 1994). Deletion mapping
studies of primary bladder tumours indicate the presence of
two independent tumour-suppressor loci on chromosome 9,
located proximally on 9p and 9q (Ruppert et al., 1993; Keen
and Knowles, 1994). In two independent studies, the 9p locus
has been mapped to the 9p21-22 region (Caims et al., 1994a;
Stadler et al., 1994).
The 9p21-22 region is also implicated in tumour develop-
ment of a wide spectrum of other human tumours, including
familial and sporadic melanoma (Cannon-Albright et al.,
1992; Fountain et al., 1992; Hussussian et al., 1994; Kamb et
al., 1994a). The location of the p16 cyclin-dependent kinase 4
vnibitor (Cdk41) gene at 9p21 has led to the hypothesis that
inhibitors of GI/S cell cycle progression may show tumour-
suppressor function and hence have oncogenic activity
if homozygously lost through deletion and/or mutation
(reviewed by Hartwell and Kastan, 1994; Marx, 1994a). In
addition to p16 (Serrano et al., 1993), three other Cdk
inhibitors have been identified: p15 (Hannon and Beach,
1994), p21 (El-Diery et al., 1993; Harper et al., 1993; Xiong
et al., 1993a) and p27 (Polyak et al., 1994a; Toyoshima and
Hunter, 1994) and these too have the potential to act as
tumour-suppressors or to confer growth advantage in vitro.
Transcription of p21 is stimulated by p53 (El-Deiry et al.,
1993) and by cell senescence (Noda et al., 1994) and expres-
sion ofp21 protein is reduced in cells with null p53 (Xiong et
al., 1993b). The p15 and p27 inhibitors are each implicated in
TGF-p-mediated GI phase arrest (Hannon and Beach, 1994;
Polyak et al., 1994b). The potential role of the p27 gene in
cancer is, as yet, undetermined.
A number of cell lines have been established from bladder
cancers, and these have been used extensively as in vitro
models of neoplastic urothelial cell behaviour (reviewed
Masters et al., 1986). Bladder cancer cell lines typically show
complex karyotypes that reflect the genesis and evolution of
the cancer and also the selection pressures imposed during
adaptation to long-term survival in vitro. We have used the
polymerase chain reaction (PCR) to screen a panel of well-
characterised bladder cancer cell lines for homozygous loss of
p15, p16 and p27 gene sequences.
Materials and etod
Cell lines
In total, 17 established human bladder cell carcinoma cell
lines were used: RT4, RT112, HT1376, HT1197, COL0232,
KK47, VM-CUB-1, VM-CUB-3, 253J, EJ, HU456, HU961T,
MGH-U2, T24, TCCSUP, HCV29 and SCaBER. These cell
lines have been reviewed and referenced by Masters et al.
(1986). The cell lines were m tained in a 1:1 mixture
of RPMI-1640 and Dulbecco's modified Eagle medium
(DMEM) with 5% fetal bovine serum (FBS), as described
previously (Trejdosiewicz et al., 1985).
Cytogenetic analysis
Cultures of bladder cancer cell lines in exponential growth
were exposed to 0.2Il ml1- colcemid (Sigma) in growth
medium for 17 h. Cells were removed from the substrate with
a solution of0.25% (w/v) trypsin and 0.02% (w/v) EDTA in
phosphate-buffered saline (PBS) for 5 min and incubated for
15 min in 0.075 M potassium chloride before washing three
times in Carnoy's fixative. Slides were analysed by GTL
banding and 3-6 metaphases were examined for each cell
line.
DNA extraction
DNA extractions were performed using standard procedures
involving digestion with proteinase K in the presence of
sodiumn dodecyl sulphate (SDS) followed by phenol/chloro-
form extractions and ethanol precipitation. The integrity of
DNA for each cell line was confirmed by PCR for an
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unrelated gene (below) and the same DNA preparation was
used in all subsequent analyses. The passage number of the
cell line stocks used is shown in Table I.
Arbitrar} primed PCR (AP-PCR)
AP-PCR was used to obtain genomic fingerprints' of the cell
lines and was performed on 50 ng DNA in a 25 ,Il reaction
volume containing 10 mM Tnrs pH 8.3, 50 mM potassium
chloride, 0.125 mM each dNTP, 5 mM magnesium chloride,
1.6ylM oligonucleotide, 1 lLCi [32PJz-dATP and 1 U AmpliTaq
(Perkin Elmer). After incubation at 94°C for 4 min, five
cycles of PCR were performed at 94'C for 1 min, 35'C for
1 min and 72'C for 1 min, followed by 30 cycles at 95°C for
1 min, 50'C for 1 min and 72°C for 1 min with a final exten-
sion at 72°C for 10 min. Samples were run on 5% polyac-
rylamide sequencing gels. Random oligonucleotide sequences
of 20-28 base length were used to generate DNA banding
fingerprints. The results described here refer specifically to
oligonucleotide BOl (Table II).
PCR
PCR was performed on 100 ng each of genomic DNA
extracted from the human bladder cell lines and from human
placental DNA (Sigma) included as positive control. Primer
sequences are shown in Table II.
For amplification of p15. primers pl5(2)F and pl5(2)R
were used to amplify a 430 bp product from exon 2 of the
p15 gene, as descnrbed by Jen et al. (1994). The reaction mix
consisted of 67 mM Tnrs pH 8.8. 16.6 mM ammon.ium sul-
phate. 6.7 mM magnesium chloride, 10 mM A-mercapto-
ethanol. 6% (v v) dimethylsulphoxide (DMSO), 1.25 mM
dNTPs, 1 iLM of each oligonucleotide primer and 5 U of
AmpliTaq. The PCR cycling conditions were denaturation
for 2 min at 95'C followed by 35 cycles of denaturation at
Table I PCR amplification of DNA from bladder cancer cell lines
Cell line PCR product
passage no.' p15 p'6 p27 LD78a
COL0232 (5) - - + +
EJ 72b + + + +
HCV29 31 - - + +
HT1197 63 + + + +
HT1376 70 + + + +
KK47 24 + + + +
RT4 61 - - + +
RT112 77 - - + +
SCaBER (4) + + + +
VM-CUB-1 (3) - - + +
VM-CUB-3 27 - - + +
TCCSUP 70 + + + +
253J94 - - + +
aWhere absolute passage number is unknown, number of passages
since receipt ofcell line is shown in parentheses. 'Same result found for
MGH-U2. HU%1T. T24 and HU456-
95'C for 30 s, reannealing at 66'C for 1 min and extension at
70'C for 1 min, with a final extension at 70'C for 5 min.
For all other PCR reactions, each 50 jil reaction mix con-
tained 10 mM Tris pH 8.3, 50 mM potassium chloride,
0.2 mM dNTPs, 2 mM magnesium chloride, 1 ;LM of each
oligonucleotide primer (except forp16, where 0.15 jiM of each
oligonucleotide was used) and 1 U AmpliTaq. p16 primers
were chosen that span an intron-exon boundary of the
human Cdk4I (pl6) gene and amplify a 167 bp product by
PCR (Nobori et al., 1994). PCR cycling conditions were
denaturation at 95'C for 1 mn, reannealing at 62'C for 30 s
and extension at 72'C for 30 s for a total of 40 cycles, with a
final extension at 72°C for 10 min. In all cases where a
negative results was obtained, the reaction was repeated.
PCR primers, p27AF and p27AR, were selected for the
human p27 gene from cDNA sequence available from the
Genbank database (accession number U10906). The PCR
cycling profile for p27 was denaturation at 95'C for 1 min,
reannealing at 60'C for 30 s and extension at 72°C for 30 s
for a total of 40 cycles, with a final extension at 72'C for
1Ommn.
The integrity of DNA preparations was checked with
primers HMIPI and HMIP2 which amplify a 682 bp product
from the 5' flanking region of the human LD78ax gene located
on chromosome 17q (Hirashima et al., 1992). The PCR
cycling profile for the LD78& primers was denaturation at
95'C for 1 min, reannealing at 60'C for I min and extension
at 72'C for 1 min for a total of 30 cycles, with a final
extension at 72'C for Omin.
PCR products from individual experiments were pooled
and run on 2% agarose gels and visualised with UV light
after staining with ethidium bromide. The 186 bp PCR prod-
uct obtained with the p27 primers was confirmed as the
correct sequence by blotting the gel onto Hybond N (Amer-
sham International) and hybnrdising with oligonucleotide
p27BF derived from the internal sequence.
Results
AP-PCR
Companrson of genomic 'fingerprints' generated by arbitrary
primed PCR revealed a single band loss from the EJ, MGH-
U2, HU961T. T24 and HU456 cells which was retained in
the other cell lines (Figure 1). These results are consistent
with earlier reports based respectively on isoenzyme analysis
and minisatellite probes which suggested cross-contamination
of these particular cell lines (O'Toole et al., 1983; Masters et
al.. 1988).
Cvtogenetic analysis
Although the karyotypes of the cell lines have been
previously reported. it was felt important to obtain specific
karyotypes for the sublines used in this study in order to
circumvent problems of genotypic drift. Cytogenetic analysis
of the cell lines revealed karyotypes ranging from near di-
Table II Oligonucleotide sequences
Gene Primer Position Sequence
pl5 p15(2)F Forward 5'-CCTTAAATGGCTCCACCTGC-3'
pl5(2)R Reverse 5'-CGTTGGCAGCCTCATCG-3'
pl6 pl6f Forward 5'-GGAAATTGGAAACTGGAAGC-3'
pl6r Reverse 5'-CTGCCCATCATCATGACCTG-3'
p 7 p27AF Forward 5'-CAAACGTGCGAGTGTCTAAC-3'
p27AR Reverse 5'-AATCGAAATTCCACTTGCGC-3'
P27BF Internal 5'-CAGAGACATGGAAGAGGCGA-3'
LD78a HMIPI Forward 5'-CTAGGCACCTGACATATTGAC-3'
HMIP2 Reverse 5'-TTCTGAGCAGGTGACGGAATG-3'
- BOll - 5'-GTCAGTTAAGCAGGAAGGGACTAAC-3'
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Fugwe 1 AP-PCR analysis of DNA from human bladder
tumour cell lines. AP-PCR was performed with primer BOll and
the products run on a 5% polyacrylamide sequencing gel. The
arrow locates the position of the band that is lost in the cell lines
thought to be derived from the same originating cell line. T24
(not shown on the gel) also showed loss of the same band. Lane
1, normal human placental DNA; lane 2, EJ; lane 3, RT112; lane
4, HU456; lane 5, HT1197; lane 6, HCV29; lane 7, HT1376; lane
8, SCaBER; lane 9, VM-CUB-3; lane 10, VM-CUB-1; lane 11,
HU961; lane 12, KK47; lane 13, COL0232; lane 14, MGH-U2;
lane 15, RT4; lane 16, normal human placental DNA.
ploid to near pentaploid with complex rearrangements of
some chromosomes. Chromosome 9p was targeted as a
region of special interest and the results are summarised in
Table III and illustrated in Figure 2.
Detection ofcyclin-ependent kinase inhibitor gene sequences
These results are summarised in Table I and illustrated in
Figure 3. Using the specific pi6 primers, the expected 167 bp-
sized single product was amplified by PCR from human
placental DNA (included as a positive control) and with
DNA from ten of the 17 bladder cell lines. Using the same
optimised PCR conditions, no product could be amplified
from any of the remaining seven cell lines (RT4, RT112,
VM-CUB-1, VM-CUB-3, COL0232, 253J and HCV29). The
ten p16-positive cell lines included all five of the cell lines
suspected of cross-contamination. When only independent
cell lines were considered, 6/13 were positive for p16.
EJ
9 del(9)(p21-22:)
KK47
addig)Dn2l-221
VM-CUB-1
COL0232
9 der(9;14)(qlO;qlO)
Is daIcf79)p1l3;p21l-22 1
Fge 2 Partial karyotypes of four human bladder tumour cell
lines to illustrate normal and rearranged copies of chromosome 9.
The specific pi5 primers amplified the expected single
430 bp product from the control human placental DNA and
from the same ten bladder cell lines which were positive for
pi6 (above), including all five cell lines suspected of cross-
contamination. All seven p16-negative cell lines failed to
amplify any product with the p15-specific primers.
Tabe M Chromosome 9 abnormalities in bladder cancer cell lines
Other 9
Chromosome E:xpected Observed No. of Rearrangement rearrangements
Cell line no. andploidy no. of9's no. of9's normal 9's affecting 9p not affecting 9p 9p status
HCV29 47 2 1 1 - - Monosomy
near diploid
COL0232 55 2 2 1 dic (7;9)(pl3;p21-22) - Loss of
hyperdiploid 9p21-22+9pter
SCaBER' 106- 10 near 5 6 4 2 copies of der - Loss of all 9p in
pentaploid (9;14)qlO;qlO) 2!6 9's
VM-CUB-3 46 2 2 2 - - Unaffectedb
diploid
TCCSUP 71 -73 3 3 3 - - Unaffectedb
near triploid
KK47a 58 3 2 1 9p21-22 - 9p21-22 terminal
near triploid rearrangement deletion + other
possibles
EJa 91 4 4 2 2 x 9's with del - 9p21-22 terminal
near tetraploid (9)(p21-22:) deletion in 2/4 9's
RT4 79-82 4 3 2 marker with most of - Loss of 9p
near tetraploid 9q but no 9p
HTI197 74-79 3 4 1 2 x 9'swith - Loss of 9p in 3 4
near triploid der(9;?)(qlO;?) and 9's
marker chromosome
with loss of all 9p
253J 59 3 3 3 - - Unaffectedb
near triploid
HT1376' 104-107 5 4-6 3-4 i(9q) Two copies9q Loss of9p in 1,5
near pentaploid rearrangement 9's
RTI 12 47 2 2 1 - Rearrangement Unaffectedb
near diploidy of 9q34
VM-CUB-1 75 3 3 2 der (9;14)(qlO;qlO) - Loss of 9p in 1 3
near triploid 9's
aIndicates cell lines from which p16 was amplified by PCR. bNo change in 9p.CDKI in bladder canoer
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Fgre 3 PCR analysis of human bladder tumour cell line DNA.
(a) Agarose gel showing 430 bp PCR product obtained with
primers specific for p15. (b) Products of PCR performed with
primers specific for p16 and LD78a gene sequences were pooled
for each cell line and run on an agarose gel. The top band
corresponds to the 682 bp LD78r PCR product. The lower band
corresponds to the 167 bp p16 PCR product. (c) Products of PCR
performed with pnrmers specific for p27 and LD78&x gene
sequences were pooled for each cell hne and run on an agarose
gel. The top band corresponds to the 682 bp LD78rx PCR prod-
uct. The lower band corresponds to the 186 bp p27 PCR product
which is present in all cell lines. (d) Hybridisation of Southern
blot of gel B with primer B27BF. Lane 1. control human placenta
DNA, lane 2. COL0232; lane 3. EJl lane 4. HCV29: lane 5.
HT1 197: lane 6. HT1376; lane 7. HU456 (equivalent to El cells-
see text): lane 8. KK47; lane 9. RT4: lane 10. RT1 12: lane 11.
SCaBER; lane 12. VM-CUB-1: lane 13. VM-CUB-3. lane 14.
TCCSUP: lane 15. 253J.
Using the p27 primers. a single PCR product of 186 bp
was amplified from control DNA and from all of the 13
independent bladder cell lines. The integrity of all the
genomic DNA preparations was confirmed by successful
amplification of a 682 bp product from the 5' flanking region
of the human LD78a gene on chromosome 17q.
Discussio
Recent advances in understanding how regulation of the cell
cycle is achieved through the coordinated activity of cycin-
dependent kinases and checkpoint controls has revealed
groups of genes with hitherto unforeseen oncogenic and
tumour-suppressor potential (Hartwell and Kastan, 1994:
Marx. 1994a). The Cdk4I (pl6) gene is one such candidate
and resides within the critical deleted region 9p21-22
implicated in tumour development progression of a wide
spectrum of human tumours. In particular. the p16 gene is
homozygously lost with high frequency in cell lines derived
from a large range of human tumours. including bladder
(Kamb et al.. 1994b; Nobori et al.. 1994). This has important
implications for bladder cancer as the grade and stage
independence of the chromosome 9p changes would suggest
that, ifp]6 is the putative tumour suppressor. deregulation of
cell cycle control is an important initiating event in human
bladder cancer. However, the apparently higher frequency of
p16 loss in bladder cell lines compared with the primary
tumour counterparts (Cairns et al., 1994b; Spruck et al.,
1994) has thrown the role ofp16 as a major multiple tumour-
suppressor gene into some dispute (Bonetta, 1994; Marx,
1994b: Wainwright. 1994). An alternative hypothesis is that
loss ofp16 confers a selective growth advantage during adap-
tation of tumour cells to culture and hence is important in
the generation of bladder cancer cell lines (Cairns et al.,
1994b; Spruck et al., 1994; Yeager et al., 1995). A definitive
answer to this debate is hindered by the problems of isolating
tumour cell DNA uncontaminated by normal stromal cell
DNA.
In this study, homozygous loss of the p15 and p16 genes
was associated with 54% (7 13) bladder cancer cell lines.
Kamb et al. (1994b), have previously reported homozygous
p16 gene deletions from 33% (5 15) bladder cancer cell lines
but did not name the cell lines used. The potential problems
of long term cross-contamination of cell lines underlines the
importance ofindividual cell line pedigree in such studies.
The cell lines MGHU2. HU961, T24, HU456 and EJ,
although received originally (c. 1978) from different sources,
were revealed to have identical DNA banding patterns on
AP-PCR-generated fingerprints and furthermore, have pre-
viously been reported to denrve from one originating cell line
(O'Toole et al., 1983; Masters et al., 1988). Had these five
cell lines been independently included in the p16 gene
analysis. the results would have suggested p16 gene loss from
only 41% (7 17) of lines.
Our findings agree well with Spruck et al. (1994), who also
found p16 loss in 54% bladder cancer cell lines. Of the 13 cell
lines studied by Spruck et al. (1994) five were duplicated in
our study (RT4, HT1376, TCCSUP, SCaBER, T24/EJ) and
of these. the SCaBER line was revealed to contain a mutated
pi6 sequence. When combined, the data from these two
studies suggest that from a total of 21 cell lines. p16 was
homozygously lost from 62% (13) bladder cancer cell lines. It
has recently been suggested that the high incidence of
homozygous deletions around the 9p21 region may be a
mechanism by which both pl6 and the neighbouring p15
gene are efficiently and simultaneously inactivated (Jen et al.,
1994) and our results support this hypothesis.
Cytogenetic analysis has confirmed the frequent involve-
ment of chromosome 9p in bladder cancer cell lines, reminis-
cent of the involvement of chromosome lp rearrangements
in Wilms' tumours (reviewed by Junien and Henry, 1994).
Nevertheless, the seven p16-negative bladder cancer cell lines
all contained at least one cytogenetically normal 9p21 region,
demonstrating that loss of the pl6 gene was too small to be
detected cytogenetically. This is consistent with the data of
Nobori et al. (1994) who found that deletions at 9p21 in
tumour cell lines were centred on the pi6 gene and were
often small. In terms of the likely succession of genotypic
changes, it seems probable that many of the chromosome 9p
rearrangements preceded changes in ploidy, as three cell lines
(SCaBER, EJ and HTI 197) revealed more than one copy of
the same derivative 9p chromosome and three p16-negative
cell hnes (VM-CUB-1, RT4 and 253J) contained more than
one cytogenetically normal copy of chromosome 9. It is also
worth noting that chromosome 9p rearrangements were
detected in five of the six cell lines from which a pi6 PCR
product was amplified: further studies will be needed to
determine whether these cell lines actually transcribe and
translate a functional pi6 gene product before this can be
taken as prima facie evidence for alternative tumour-
suppressor genes residing at 9p2l-22 in bladder cancer
(Bonetta, 1994; Spruck et al., 1994).
The adaptation of tumours to growth in vitro places
rigorous selection pressures on the individual tumour cells.
Indeed, compared with normal bladder epithelium (Southgate
et al., 1994), the majority of primary bladder tumours do not
readily adapt to in vitro growth (Niell and Soloway, 1983,
and unpublished observations). Derangement of cell cycle
control through loss of Cdk inhibitor function may provide
an adaptive growth advantage in vitro. Expression of the
p53-associated Cdk inhibitor protein, p21, has been shown to
De reduced in cells with p53 mutations (Xiong et al., 1993).
Thus, whereas the p21 gene is not a direct target, loss of
expression through p53 mutation can result in a phenotypic
loss of suppressor function. Spruck et al. (1994) showed that,
of the six bladder cancer cell lines that were pi6 positive,
*
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only one cell line contained a wild-type p53 gene.
Homozygous loss of p53 is a relatively late event in the
progression of bladder cancer (Sidransky et al., 1991) and, as
yet, it is unknown whether loss ofp16 or p21 function could
offer differential survival benefits in vitro. Our studies suggest
that the p27 gene is not commonly homozygously deleted in
human bladder cancers. However, further studies will be
needed to determine whether loss of p27 protein function is
important either in bladder tumour progression and/or in the
evolution of bladder tumour cell lines.
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